Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 Substudy 01G: Pembrolizumab + HER3-DXd in Advanced NSCLC
NCT06731907Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2025
- Primary completion
- Mar 2032
- Countries
- 11
01
Overview
A Phase 2 trial of patritumab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Mar 2025; status: recruiting.
02
Drugs
patritumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06731907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06731907.